C. J. Ryan, et al., “Interim Analysis (IA) Results of COU-AA-302, a Randomized, Phase III Study of Abiraterone Acetate (AA) in Chemotherapy-Naive Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC),” Journal of Clinical Oncology, Vol. 30, 2012.

has been cited by the following article:

• TITLE: Castrate Resistant Metastatic Prostate Cancer: Options for a Patient in 2012

  AUTHORS: Asim Ahmad, Winston Tan

  KEYWORDS: Castrate; Resistant; Prostate; Cancer; Treatment; Review

  JOURNAL NAME: Open Journal of Urology, Vol.2 No.3A, October 30, 2012

  ABSTRACT: Castrate resistant metastatic prostate cancer remains a fatal disease. Through preclinical studies and clinical trials, a multitude of options have been made available to prolong the life of these patients, as well as improve quality of life. First line treatment options following tumor progression after androgen deprivation therapy include Provenge and docetaxel. Several options are available as second line treatment, including cabazitaxel, abiraterone, and enzalutamide. Many drugs currently being studied are very promising, such as alpharadin. Here we review treatment options for patients suffering from disease progression after androgen deprivation therapy, and offer a review of the current available options for the clinician.